Peer Reviewed Articles
Musch MW, Mamah D, Gawenis LR, Zhang Z, Ellsworth W, Shalowitz D, Efthimiou P,…, Barrett TA. “T-cell activation causes diarrhea by increasing intestinal permeability and downregulating epithelial Na+/K+ATPase” Journal of Clinical Investigation, 2002, 110:1739-1747.
Efthimiou P, Markenson JA. “Role of Biologic Agents in the Treatment of Immune Mediated Inflammatory Diseases”. Southern Medical Journal, 2005, 98(2): 192-204.
Efthimiou P, Paik P, Bielory L. “Diagnosis and Management of Adult Onset Still’s Disease (AOSD)”. Annals of Rheumatic Diseases, 2006; 65: 564-572.
Ramaswami R, Efthimiou P, Gnanasekaran I. “Musculoskeletal Manifestations of Dialysis; an update” Clinical Rheumatology, 2006 Jul;25(4):440-2.
Efthimiou P, Schwartzman S, Kagen L “Possible Role for TNF-Inhibitors in the Treatment of Resistant Dermatomyositis and Polymyositis”. Annals of Rheumatic Diseases, 2006, Sep;65(9):1233-6.
Rosenkranz ME, Agle LM, Efthimiou P, Lehman TJ. “Systemic and localized scleroderma in children: current and future treatment options”. Paediatric Drugs. 2006;8(2):85-97.
Ogden NS, Ward CM, Kontzias A, Wyatt ST, and Efthimiou P. “Adult Onset Still Disease: 20 Clinical Pearls” Journal of Musculoskeletal Medicine, 2006; 23:788-800.
Efthimiou P. “Tumor Necrosis Factor alpha in inflammatory myopathies: pathophysiology and therapeutic implications”. Seminars in Arthritis and Rheumatism, 2006 Dec; 36(3): 168-72.
Efthimiou P and Georgy S.¨Pathophysiology and Management of Adult Onset Still’s Disease”. Seminars in Arthritis and Rheumatism, 2006 Dec; 36(3): 144-52.
Efthimiou P and Sood S. “QuantiFERON TB Gold Test: the New Standard for Screening of Latent Tuberculosis in Patients with Rheumatoid Arthritis?” Annals of Rheumatic Diseases, 2007 Feb; 66(2):276
Blake AD, West FM, Ghafoor S, and Efthimiou P. “Somatostatin Involvement in Rheumatoid Arthritis” Current Rheumatology Reviews, 2007; 3:31-36.
Efthimiou P,Ward MC, Kontzias A, Ogden NS. “Adult Onset Still’s disease: Can New Pathophysiologic Clues Guide Future Targeted Treatments?” Nature Reviews Rheumatology, 2007 Jun; 3(6): 328-335.
Efthimiou P, Kumar S. “Development of Olecranon Bursitis after Treatment with Abatacept in a Patient with Rheumatoid Arthritis” Contemporary Topics in Rheumatoid Arthritis, 2007; 1(3): 6-8.
Efthimiou P “Translating Basic Research Findings into Therapeutic Advances in Rare Rheumatologic Disorders: Lessons Learned from Adult Onset Still’s Disease” Contemporary Topics in Rheumatoid Arthritis, 2007; 1(4): 4-9.
Efthimiou P, Blanco M. “Intravenous Gammaglobulin and Thalidomide may be an Effective Therapeutic Combination in Refractory Scleromyxedema” Seminars in Arthritis and Rheumatism, 2008 Dec;38(3):188-94
Kontzias A and Efthimiou P. “Adult-Onset Still’s Disease : Pathogenesis, Clinical Manifestations and Therapeutic Advances” Drugs, 2008; 68(3):319-337
Efthimiou P, Nasis O, Lehman TJ. “Aortic aneurysm in Takayasu’s arteritis” Journal of Rheumatology, 2007, Nov;34(11):2312.
Yavari N, Platt H, Michel R, Navarro C, and Efthimiou P.” Environmental and Occupational Exposure in Rheumatoid Arthritis” Journal of Musculoskeletal Medicine, 2008; 25:130-136.
Efthimiou P et al. “Autoinflammatory syndromes and infections: pathogenetic and clinical implications”. Clinical Experimental Rheumatology, 2008; Jan-Feb;26(1 Suppl 48):S53-61.
Efthimiou P, Nasis O, Russell LA. “Classic presentation of a rare disease: melorheostosis”. Journal of Rheumatology, 2008 Jun;35(6):1169.
Souayah N, Chodos A, Krivitskaya N, Efthimiou P, Lambert WC, Sharer LR. “Isolated severe vasculitic neuropathy revealing sarcoidosis”. Lancet Neurology. 2008 Aug;7(8):756-60.
Efthimiou P.” Preoperative management of patients with rheumatoid arthritis underdoing elective surgery while being treated with abatacept”. Contemporary Topics in Rheumatoid Arthritis, 2008; 2(4):6-9.
Efthimiou P, Blanco M. “Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus and Potential Biomarkers” Modern Rheumatology, 2009;19(5):457-68
Kukar M, Petryna O, and Efthimiou P. “Biological targets in the treatment of Rheumatoid arthritis: A Comprehensive review of Current and In-development Biological Disease Modifying Anti-Rheumatic Drugs”, Biologics:Targets &Therapy, 2009:3 443–457
Petryna O and Efthimiou P. “An Unusual Cause of Lower Back Pain”, Journal of Rheumatology, 2009 Nov;36(11):2556
Efthimiou P, Kukar M, Kagen LJ. “Severe Adult Onset Calcinosis in a patient with a history of Juvenile Dermatomyositis”, Journal of Rheumatology, 2010 Jan;37(1):194
Efthimiou P, Petryna O. ”Headache from Cavernous Sinus Thrombosis in Adamantiades-Behcet’s Disease”, Journal of Clinical Rheumatology, 2010; Dec;16(8):409
Efthimiou P, Kukar M. “Complementary and Alternative Medicine: Proposed mechanism of action and efficacy of commonly used modalities in Rheumatoid arthritis, A Comprehensive Review of the Recent Literature”, Rheumatology International; 2010 Mar; 30(5): 571-86
Efthimiou P, Kukar M. “Complementary and Alternative Medicine in Rheumatoid Arthritis: No Longer the Last Resort”, HSS Journal, 2010; 6: 108–111
Petryna O, Yavari N, Efthimiou P. “Occupational and Environmental Exposures in Lupus and Systemic Sclerosis: A preventable Risk Factor?” Journal of Musculoskeletal Medicine, 2010; 27:395-402.
Efthimiou P, Kukar M, Krishnan P. “Posterior Reversible Encephalopathy Syndrome (PRES): a severe manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE)” Arthritis and Rheumatism, 2010 Jun;62(6):1692.
Efthimiou P, Petryna O, Kukar M, Gold M.” Characteristic neuroimaging findings in posterior reversible encephalopathy syndrome (PRES) in SLE: Reply.” Arthritis and Rheumatism, 2011 Jan; 63(1):309-10
Efthimiou P, Kukar, Hersh A. “Rituximab and Lupus Interstitial Lung Disease: Friend or Foe?” International Journal of Rheumatic Diseases, 2011 Feb; 14(1): e3-4.
Efthimiou P, Pokharna H, Kukar M, Hennessey K. “PCP Chemoprophylaxis is Essential for Lymphopenic Dermatomyositis Patients Treated with Immunomodulators”, Muscle & Nerve, 2011 Jun; 43 (6):918-9.
Efthimiou P, Kukar M. “Lupus Pernio: Sarcoid-specific Cutaneous Manifestation Associated with Chronic Sarcoid Arthropathy”, Journal of Clinical Rheumatology, 2011; 17 (6): 343.
Mehta B and Efthimiou P. “Latent Tuberculosis in RA: The Disease and the Diagnosis”, Journal of Musculoskeletal Medicine, 2011; 28 (7): 249-55
Mehta B and Efthimiou P. “Latent Tuberculosis in RA: Current Diagnostic Techniques and Treatment”, Journal of Musculoskeletal Medicine, 2011; 28 (8): 300-307
Mehta B, Mueller W, and Efthimiou P. “CNS vasculitis: A protean manifestation of HIV/AIDS”, Journal of Musculoskeletal Medicine, 2011; 28 (12): 462-464
Mehta B and Efthimiou P. “Radiographic Improvement in Sarcoid Arthropathy after Infliximab Treatment”, Journal of Rheumatology, 2012; 39;664-5
Kukar M and Efthimiou P. “Therapeutic Armamentarium against Rheumatoid Arthritis in the New Decade: not there yet, but getting closer”, European Musculoskeletal Review; www.touchmusculoskeletal.com, May, 2012
Mehta B and Efthimiou P. “Ferritin in Adult onset Still’s disease (AOSD): just a useful innocent bystander?” International Journal of Inflammation, 2012; 2012:298405. Epub Mar 25
Kontzias A and Efthimiou P. “”The Use of Canakinumab, a Novel IL-1β Long Acting Inhibitor, in Refractory Adult-onset Still’s Disease.” Seminars in Arthritis and Rheumatism, 2012 Oct; 42(2):201-5.
Petryna O, Cush JJ, and Efthimiou P. “IL-1 Trap Rilonacept in Refractory Adult-onset Still’s Disease”, Annals of Rheumatic Diseases, 2012; 71: 2056-2058
Efthimiou P, Moorthy N, Mavragani CP, Skokos D, Fautrel B “Editorial: Adult- onset Still’s Disease and Autoinflammation” International Journal of Inflammation, 2012:964751. Epub 2012 Aug 29
Hsieh J, Kadavath S, and Efthimiou P. “Can Traumatic Injury Trigger Psoriatic Arthritis?” Clinical Rheumatology, 2014 May;33(5):601-8. doi: 10.1007/s10067-013-2436-7
Kadavath S and Efthimiou P. “Canakinumab in Autoimmune and Autoinflammatory Rheumatic Diseases.” Expert Opinion on Orphan Drugs, Jan 2014, Vol. 2,1, pp 27-35.
Efthimiou P, Kadavath S, Mehta B.”Life-threatening complications of adult-onset Still’s disease. Clinical Rheumatology. 2014 Mar;33(3):305-14.
Kadavath S, Zapantis E, and Efthimiou P. “A Novel Therapeutic Approach In Adult Onset Still`s Disease- Associated Pulmonary Hypertension: Targeting Interleukin 6” International Journal of Rheumatic Diseases, 2014, International Journal of Rheumatic Diseases. 2014 Mar;17(3):336-40.
Kadavath S and Efthimiou P.”Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options” Annals of Medicine. 2015 Jan 22:1-9.
Kadavath S, Bobic S, Efthimiou P. “Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren’s syndrome.” Clinical Rheumatology. 2015;34(9):1651-1652.
Afzal A, Chittalai S,Wong I, Efthimiou P. “Unmasking IgG4-related autoimmune pancreatitis from pancreatic cancer: A lesson learned” Int J Case Rep Images. 2016;7(2):123–126.
Ruiz-Irizarry Y and Efthimiou P. “Rhabdomyolysis and Polyarticular Inflammatory Arthritis May be the Initial Presentation of Chronic Myelogenous Leukemia (CML)”. J Rheum Dis Treat. 2015, 1:3
Mehta B, Zapantis E, Petryna O, Efthimiou P “Screening Optimization of Latent Tuberculosis Infection in Rheumatoid Arthritis Patients”. Arthritis, 2015;2015:569620.
Levine T, Malone J, Efthimiou P, Tandan R, Dikranian A, Levine A, Saperstein D. “H.P.A.G in Dermatomyositis and Polymyositis Treatment Registry: An Interim Analysis” J Neurol Disord 2016, 4:5, DOI: 10.4172/2329-6895.1000292
Efthimiou P, Yadlapati S. “Impact of IL-1 inhibition on fatigue associated with Autoinflammatory syndromes” Modern Rheumatology. 2016; Jan;26(1):3-8.
Yadlapati S, Efthimiou P. “Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?” Rheumatology International. 2016 May;36(5):627-33.
Yadlapati S, Efthimiou P. “Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?”. BioMed Research International, 2016; 2016: 8631061.
Bello AE, Perkins EL, Jay R, Efthimiou P. “Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis” Open Access Rheumatol. 2017 Mar 31;9:67-79. doi: 10.2147/OARRR.S131668. eCollection 2017.
Yadlapati S, Efthimiou P. “IgG4-Related Disease: A Complex Under-Diagnosed Clinical Entity” Rheumatology International, 2018 Feb;38(2):169-177
Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L,,, Speziale. “Efficacy and safety of canakinumab in patients with Still’s disease: Exposure-response analysis of pooled SJIA data by age groups”, Clin Exp Rheumatology, 2018. EPUB.
Menon S and Efthimiou P. “Tumor necrosis factor receptor associated periodic syndrome (TRAPS) in adults” Rheumatology International, 2018 Jan;38(1):3-11
Chao R, Das M, Philip C, Efthimiou P “Oxygen-Dependent Patient with Antisynthetase Syndrome Associated Interstitial Lung Disease Responds Promptly to Rituximab with Rapid Pulmonary Function Improvement” Mediterr J Rheumatol 2017; 28(3):56-59
Bottai M, Tjärnlund A, Santoni G et al. International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) “EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report” RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017.
Books, Monographs and Chapters
Efthimiou P and Paget SA. “Rheumatoid Arthritis”. Chapter in: Hospital Healthcare Europe 2003/2004, P38-39, Healthcare Publications, 2003, Campden Publishing, London, UK
Schwartzman S and Efthimiou P. “Progressive Systemic Sclerosis (PSS) and Related Disorders”. Chapter in: American College of Physicians (ACP) Expert Guide to Rheumatology, 2005, pp135-147, ACP Publications, Philadelphia, PA.
Efthimiou P and Kagen L. “Polymyositis, Dermatomyositis, and Inclusion Body Myositis”. Chapter in: Manual of Rheumatology and Outpatient Orthopedic Disorders: Diagnosis and Therapy, Fifth Edition, 2005, pp 245-252, Lippincott, Williams & Wilkins, New York, NY
Efthimiou P and Markenson J. “Psoriatic Arthritis”. Chapter in: Manual of Rheumatology and Outpatient Orthopedic Disorders: Diagnosis and Therapy, Fifth Edition, 2005, pp 318-24, Lippincott Williams & Wilkins, New York, NY
Efthimiou P. “Rheumatology”. Chapter in: Last Minute: Internal Medicine, Miksad, R. Meyer, K. and Delamora, P. McGraw-Hill. NY, NY 2008
Efthimiou P, Petryna O, Kukar M. “Complex situations in patients with adult-onset Still disease” in Autoimmune Diseases: Complex and Acute Situations, 2011, pp 221-232, Springer, NY, NY.
Efthimiou P, Kontzias A. “Adult-onset Still’s Disease” chapter in: Internal Medicine Specialty Board Review, Editor-in-Chief: R.R. Baliga, McGraw Hill, in press.
Efthimiou P, Kontzias A. “Treatment of Rheumatoid Arthritis” chapter in: Encyclopedia of Medical Immunology, Eds: Ian R.Mackay, Noel R. Rose, Springer, NY, NY, 2014.
Yadlapati S, Efthimiou P. “Cyclic Neutropenia”, chapter in: 5-minute clinical consult, 26th Ed, Ed: Frank J. Domino, Wolters Kluwer, NY, 2018
Yadlapati S, Efthimiou P. “Adult Onset Still’s Disease”, chapter in: Auto-Inflammatory Syndromes: Pathophysiology, Diagnosis, and Management, Springer-Nature, NY, 2018
Efthimiou P, Editor-in-Chief, Textbook, Auto-Inflammatory Syndromes: Pathophysiology, Diagnosis, and Management, Springer-Nature, NY, 2018
Efthimiou P and Barrett TA.
“Lamina Propria T-Cell Activation Induces Diarrhea Through A TNF-a Mediated
Down-regulation of Small Bowel Na+/K+ ATPase”, Poster Finalist, National
Associates Research Competition, ACP Annual Session, 2001, Atlanta, GA
Erkan D, Efthimiou P, Sammaritano L, Lockshin MD. “Antiphospholipid Antibody
(aPL) – Related Transient Ischemic Attacks (TIA): What is the Optimal Management?” Poster Presentation. Arthritis & Rheumatism, 2002; 46:9 (Suppl); S47
Efthimiou P, Harrison MJ, MacKenzie CR, Paget SA. “Complementary and Alternative Medicine in Rheumatoid Arthritis: No Longer the Last Resort”. Poster Presentation , Arthritis & Rheumatism, 2002; 46:9 (Suppl); S342
Efthimiou P, Rosenkranz ME, Mackenzie R, Adler R, Paget SA. “IVIG and Thalidomide Combination is an Effective Novel Therapy for Scleromyxedema”. Poster Presentation, Arthritis & Rheumatism 2003; 48:9 (Suppl); S617
Rosenkranz ME, Agle L, Efthimiou P, Onel KB, Lehman T JA.
“Is Routine Testing of Anti-Topoisomerase Antibody (Scl-70) and Anti-
Centromere Antibody (ACA) Warranted in a Pediatric Population?” Poster
Presentation, Arthritis & Rheumatism, 2003; 48:9 (Supplement);S513
Ramaswamy D, Gnanasekaran I, Nikolov N, Efthimiou P, Gour N, Paget SA.
“Musculoskeletal manifestations in patients on hemodialysis for endstage renal
Disease (ESRD): A profound change in character and incidence associated with
advancements in dialysis therapy”. Poster Presentation, Arthritis & Rheumatism
2003; 48:9 (Suppl); S533
Efthimiou P, Ivashkiv LB. “Increased FcγRI Expression in IFN-γ Primed Human
Macrophages Enhances TNF-α Production after FcγReceptor (FcγR) Crosslinking”, Poster Presentation. Arthritis & Rheumatism, 2003; 48:12 (Suppl); SY9:3621
Efthimiou P, Schwartzman S, Kagen L. “Is There a Role For Anti-TNF Therapy in Dermatomyositis and Polymyositis?” Podium presentation, 2004 EULAR, Berlin, Germany. Annals of the Rheumatic Diseases, 63: 67-67 Suppl. 1 Jul 2004.
Efthimiou P, Rosenkranz ME, Lehman TJ. “Does Etanercept Have A Role In The Treatment Of Juvenile Dermatomyositis?” Annals of the Rheumatic Diseases, 2005; 64(Suppl III):573.
Efthimiou P, Rosenkranz ME, Hays A, Kagen LJ. “Etanercept: A Novel Treatment Of Dysferlinopathy And Limb-Girdle Muscular Dystrophy Type 2b” Annals of the Rheumatic Diseases, 2005; 64(Suppl III):575.
West FM, Blake AD, Efthimiou P. “Somatostatin Regulates the TNF-alpha Stimulated Extracellular Regulated Kinase Cascade of Human Rheumatoid Arthritis Synoviocytes” Arthritis & Rheumatism, 2006; 54:9 (Suppl); S218
Hersh AB, Efthimiou P. “Rituximab in Lupus Pneumonitis: Breath Easier”. Journal of Allergy & Clinical Immunology, 2007; 119:1 (Suppl); S260
Sood S, Sharma R, Efthimiou P. “Quantiferon TB-Gold Testing and Rheumatoid Arthritis?” Annals of the Rheumatic Diseases, 2007; 66(Suppl 1):A60
Sharma R, Hersh AB, Efthimiou P. “Rituximab Use in Lupus Pneumonitis” Annals of the Rheumatic Diseases, 2007;66(Suppl 1):A58
Paralejo BM, Aquino M, Efthimiou P. “Increased Levels of IL-6 and Ferritin as Potential Biomarkers in Adult onset Still’s DIsease”. Annals of Allergy Asthma& Immunology, 2008; 100:1 (Suppl); A59-60
Aquino M, Efthimiou P. “Corneal Ulceration as the Initial Manifestation of Underlying Cryoglobulinemia”. Annals of Allergy Asthma& Immunology, 2008; 100:1 (Suppl); A58
Petryna O, Hooda A, Mankotia N, Efthimiou P. “Adult onset Still’s Disease Presenting with a Symmetric Linear Cutaneous Eruption of the Lower Extremities and Macrophage Activation Syndrome”. Poster presentation, ACP Downtown Regional Meeting, ACP Associate Poster Competition; 2009, NY, NY
Petryna O, Efthimiou P. “Rilonacept Treatment of Refractory Adult Onset Still’s Disease”. Poster presentation, American College of Rheumatology, 73rd Annual Scientific Meeting; 2009, Philadelphia, PA
Petryna O, Kontzias A, Kirou K, Efthimiou P “Hyperferritenemia in Adult honest Still’s Disease is Independent of Plasma Type I Interferon Activity”. Poster presentation, EULAR 2010 Scientific Meeting; June 16-19, 2010, Rome, Italy
Petryna O, Cush J, Kontzias A, Efthimiou P “Successful use of of the IL-1 trap Rilonacept in AOSD refractory to Anakinra” Poster presentation featured in EULAR Poster Tour, EULAR 2011 Scientific Meeting; May 25-29, 2011, London, UK
Mehta B, Sohn B, and Efthimiou P “Combining Tuberculin Skin Test and Interferon Gamma Release Assays for Latent Tuberculosis Infection Screening May Be Necessary for the Exclusion of Latent Tuberculosis in a High Risk Individuals with RA” Arthritis & Rheumatism, 2011; 63:10 (Supplement);S463-4, Poster presentation featured in ACR Poster Tour, American College of Rheumatology, 75th Annual Scientific Meeting; 2011, Chicago, IL
Efthimiou P, Petryna O,Mehta B, Kontzias A, Cush JJ “Successful use of Canakinumab in AOSD refractory to Short Acting IL-1 Inhibitors” Poster presentation, EULAR 2012 Scientific Meeting; June 6-9, 2012, Berlin, Germany
Mehta B, Zapantis E, Efthimiou P “A Proposed Effective Strategy for the Screening of Latent Tuberculosis Infection in Rheumatoid Arthritis Patients” Poster presentation, EULAR 2012 Scientific Meeting; June 6-9, 2012, Berlin, Germany
Kadavath S, Zapantis E, Mehta B, Efthimiou P “Effectiveness Of Combining Tuberculin Skin Test And Interferon Gamma Release Assays As A Screening Strategy For Detecting Latent Tuberculosis Infection In High Risk Patients With Systemic Lupus Erythematosus”, Poster presentation, EULAR 2013 Scientific Meeting; June 12-15, 2013, Madrid, Spain
Bobic S, Kadavath S, Zapantis E, Efthimiou P “Use Of B Lymphocyte Stimulator (Blys) Inhibitor Belimumab May Be Associated With Decreased Multiple Serum Biomarkers In Patients With Primary Sjögren’s Syndrome (pSS)”, Poster presentation, American College of Rheumatology, 77th Annual Scientific Meeting; 2013, San Diego, CA
Mehta B, Efthimiou P et al “Raynaud’s Phenomenon and African American Race Are Independently Associated With Non-Hodgkin’s Lymphoma In Sjogrens Syndrome Patients: Findings From a United States National Study” Poster presentation, American College of Rheumatology, 77th Annual Scientific Meeting; 2013, San Diego, CA
Efthimiou P, Kadavath S, Bhatta A, Charles E, Dustin L “Characterization of Phenotype and Immunoglobulin Genes of Auto-reactive B Cells in Sjogren’s Syndrome” Poster presentation, EULAR 2014 Scientific Meeting; June 11-14, 2014, Paris, France
Kadavath S, Chittalai S,…, Efthimiou P, “14-3-3 ETA Protein : A Novel Biomarker for the Diagnosis of Rheumatoid Arthritis”. Poster presentation, EULAR 2014 Scientific Meeting; June 11-14, 2014, Paris, France
Mehta B, Efthimiou P “PREVALENCE OF ARTHRITIS INCREASES WITH OBESITY AND LOW SOCIOECONOMIC STATUS:EXTRAPOLATED DATA FROM A 10-YEAR UNITED STATES NATIONAL SURVEY” Poster presentation, EULAR 2015 Scientific Meeting; June 9-13, 2015, Rome, Italy.
Vasconcellos A, Chittalai S and Efthimiou P “Does 14-3-3 ETA Protein Offer Any Additional Diagnostic Value in Rheumatoid Arthritis?” Poster Presentation, American College of Rheumatology, 79th Annual Scientific Meeting; 2015, San Francisco, CA
Eugen Feist, Pierre Quartier, Bruno Fautrel, Rayfel Schneider,
Paolo Sfriso, Petros Efthimiou, Luca Cantarini, Karine Lheritier, Karolynn Leon, Chetan S. Karyekar, Antonio Speziale, Podium Presentation, 9th International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Congress, May 5-7, Cyprus
Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar C, Speziale A. “EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH STILL’S DISEASE: A POOLED ANALYSIS OF SJIA DATA BY AGE GROUPS”, Poster presentation, EULAR 2017 Scientific Meeting; June 14-17, 2017, Madrid, Spain.
Mehta B, Briggs M, Efthimiou P. “EPIDEMIOLOGY AND COMPLICATIONS OF HOSPITALIZED PATIENTS WITH ADULT ONSET STILL’S DISEASE IN UNITED STATES: A NATIONWIDE ESTIMATE”. Poster presentation, EULAR 2017 Scientific Meeting; June 14-17, 2017, Madrid, Spain.
Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar C, Speziale A. “Canakinumab Treatment in Patients with Still’s Disease: A Pooled Analysis of Systemic Juvenile Idiopathic Arthritis Data By Age Groups”, Poster Presentation, American College of Rheumatology, 81st Annual Scientific Meeting; 2017, San Diego, CA
Mehta B, Briggs M, Efthimiou P “Epidemiology of Hospitalized Adult Onset Still’s Disease in the United States”. Podium Presentation, American College of Rheumatology, 81st Annual Scientific Meeting; 2017, San Diego, CA